{"id":"sar408701","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By cross-linking CD40 and 4-1BB, SAR408701 activates dendritic cells and co-stimulates T cell proliferation and effector function. This dual engagement amplifies both innate and adaptive immune responses against cancer cells, potentially overcoming tumor immune evasion mechanisms.","oneSentence":"SAR408701 is a bispecific antibody that simultaneously engages CD40 on antigen-presenting cells and 4-1BB on T cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:33.292Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT04524689","phase":"PHASE2","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-10-26","conditions":"Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)","enrollment":57},{"nctId":"NCT04659603","phase":"PHASE2","title":"Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-03-29","conditions":"Breast Cancer Metastatic, Pancreatic Carcinoma Metastatic","enrollment":50},{"nctId":"NCT05245071","phase":"PHASE2","title":"Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-06-01","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":22},{"nctId":"NCT05071053","phase":"PHASE2","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-11-16","conditions":"Adenocarcinoma Gastric, Gastrooesophageal Cancer","enrollment":35},{"nctId":"NCT04154956","phase":"PHASE3","title":"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-02-06","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":389},{"nctId":"NCT03324113","phase":"PHASE1","title":"Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-10-17","conditions":"Neoplasm Malignant","enrollment":34},{"nctId":"NCT04394624","phase":"PHASE2","title":"Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-08-31","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":31},{"nctId":"NCT05429762","phase":"PHASE1","title":"Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-10-03","conditions":"Neoplasm","enrollment":56},{"nctId":"NCT02187848","phase":"PHASE1","title":"Evaluation of SAR408701 in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Sanofi","startDate":"2014-07-23","conditions":"Neoplasm Malignant","enrollment":254},{"nctId":"NCT05703555","phase":"PHASE2","title":"INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701","status":"WITHDRAWN","sponsor":"Erasmus Medical Center","startDate":"2024-02-16","conditions":"Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tusamitamab ravtansine"],"phase":"phase_3","status":"active","brandName":"SAR408701","genericName":"SAR408701","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SAR408701 is a bispecific antibody that simultaneously engages CD40 on antigen-presenting cells and 4-1BB on T cells to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}